Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.40 |
| ▸ | EED | O75530 | 1/20 | 0.40 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.40 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.40 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.40 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 6/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25339942 | 0.96 | IDO1 (0.45) | IDO1PKMGPR119EEDRBBP4 | |
| SCHEMBL25342059 | 0.93 | IDO1 (0.47) | IDO1PKMGPR119EEDRBBP4 | |
| SCHEMBL31738755 | 0.91 | IDO1 (0.37) | IDO1PKMGPR119EEDRBBP4 | |
| SCHEMBL25344960 | 0.87 | IDO1 (0.42) | IDO1PKMGPR119EEDRBBP4 | |
| SCHEMBL31738777 | 0.87 | IDO1 (0.37) | IDO1PKMGPR119EEDRBBP4 | |
| SCHEMBL18148459 | 0.85 | IDO1 (0.47) | IDO1PKMGPR119HRH3TRPM8 | |
| SCHEMBL20270597 | 0.85 | IDO1 (0.44) | IDO1GPR119HRH3TRPM8TRPV1 | |
| SCHEMBL31024719 | 0.82 | PKM (0.42) | IDO1PKMGPR119EEDRBBP4 | |
| SCHEMBL31024681 | 0.82 | PKM (0.42) | IDO1PKMGPR119EEDRBBP4 | |
| SCHEMBL25343196 | 0.82 | TRPM8 (0.45) | IDO1PKMGPR119EEDRBBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656642-A1 | ESTROGEN RECEPTOR PROTEOLYSIS TARGETING CHIMERA COMPOUND AND USE THEREOF | GAN & LEE PHARM CO., LTD (CN) | 2025-12-03 | — | — | EP | disclosed |
| US-20250129088-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | GAN & LEE PHARMACEUTICALS CO., LTD. (CN) | 2025-04-24 | — | — | US | disclosed |
| EP-4471033-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | Gan & Lee Pharmaceuticals Co., Ltd. (CN) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023143589-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | 甘李药业股份有限公司 | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129088-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | CRBN, UBE3A, UBE3C | IDO1 1848/4885PKM 3582/4885GPR119 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.